The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online
doi:10.1084/jem.20081056
The Journal of Experimental Medicine, Vol. 205, No. 6, 1255-1259
The Rockefeller University Press, 0022-1007 $30.00
© Timmer et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1452K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Timmer, A. M.
Right arrow Articles by Nizet, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Timmer, A. M.
Right arrow Articles by Nizet, V.
Related Collections
Right arrowRelated Articles
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

COMMENTARY

 IKKβ/NF-{kappa}B and the miscreant macrophage

Anjuli M. Timmer and Victor Nizet

A.M. Timmer and V. Nizet are at Department of Pediatrics, School of Medicine, and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093

CORRESPONDENCE V.N.: vnizet{at}ucsd.edu


ABSTRACT
Macrophage activation relies on complex intracellular signaling processes that integrate the need for rapid inflammatory responses to pathogens with the need to resolve inflammation without permanent harm to normal tissues. Patterns of aberrant macrophage activation characterize and sustain disorders of chronic inflammation, infection, and cancer. New studies now show a role for the NF-{kappa}B activator IKKβ in promoting an alternative, immunosuppressive pattern of macrophage activation, which limits the cell's tumoricidal and bactericidal capacities. As cancers and pathogens may have evolved multiple mechanisms to manipulate macrophages for their own survival, is there anything we can do about it?

© 2008 Timmer and Nizet This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jgp.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Articles

"Re-educating" tumor-associated macrophages by targeting NF-{kappa}B
Thorsten Hagemann, Toby Lawrence, Iain McNeish, Kellie A. Charles, Hagen Kulbe, Richard G. Thompson, Stephen C. Robinson, and Frances R. Balkwill
J. Exp. Med. 2008 205: 1261-1268. [Abstract] [Full Text] [PDF]

An antiinflammatory role for IKKβ through the inhibition of "classical" macrophage activation
Carol Ho Yan Fong, Magali Bebien, Arnaud Didierlaurent, Ruth Nebauer, Tracy Hussell, David Broide, Michael Karin, and Toby Lawrence
J. Exp. Med. 2008 205: 1269-1276. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS